Edition:
United Kingdom

aTyr Pharma Inc (LIFE.OQ)

LIFE.OQ on NASDAQ Stock Exchange Global Select Market

3.05USD
23 Feb 2018
Change (% chg)

$0.05 (+1.67%)
Prev Close
$3.00
Open
$3.05
Day's High
$3.05
Day's Low
$2.80
Volume
14,841
Avg. Vol
7,988
52-wk High
$6.45
52-wk Low
$2.33

Chart for

About

aTyr Pharma, Inc. is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based... (more)

Overall

Beta: --
Market Cap(Mil.): $159.70
Shares Outstanding(Mil.): 29.71
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Atyr Pharma Says On Dec 22, Co Entered Into Amendment To Loan And Security Agreement Dated As Of Nov 18, 2016

* ATYR PHARMA SAYS ON DEC 22, CO ENTERED INTO AMENDMENT TO LOAN AND SECURITY AGREEMENT DATED AS OF NOV 18, 2016 - SEC FILING

22 Dec 2017

BRIEF-aTyr Pharma reports qtrly ‍net loss per share, basic and diluted $0.43​

* aTyr Pharma announces third quarter 2017 operating results and provides corporate update

14 Nov 2017

BRIEF-Atyr Pharma files for resale of up to 23.6 mln shares of common stock by selling stockholders - SEC Filing‍​

* Atyr Pharma Inc files for resale of up to 23.6 million shares of common stock by selling stockholders - SEC Filing‍​ Source text: [http://bit.ly/2h4V7rA] Further company coverage:

14 Sep 2017

BRIEF-‍Viking Global Investors reports 9.5 pct passive stake in aTyr Pharma​

* ‍Viking Global Investors Lp reports 9.5 percent passive stake in aTyr Pharma Inc as on August 31, 2017 - SEC filing​ Source text : (http://bit.ly/2vP2d66) Further company coverage:

11 Sep 2017

Earnings vs. Estimates